311 related articles for article (PubMed ID: 33937080)
1. Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia.
Loke J; Vyas H; Craddock C
Front Oncol; 2021; 11():666091. PubMed ID: 33937080
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
Loke J; Buka R; Craddock C
Front Immunol; 2021; 12():659595. PubMed ID: 34012445
[TBL] [Abstract][Full Text] [Related]
3. Which patients with acute myeloid leukemia in CR1 can be spared an allogeneic transplant?
Craddock C; Raghavan M
Curr Opin Hematol; 2019 Mar; 26(2):58-64. PubMed ID: 30585893
[TBL] [Abstract][Full Text] [Related]
4. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience.
Loke J; Malladi R; Moss P; Craddock C
Br J Haematol; 2020 Jan; 188(1):129-146. PubMed ID: 31823351
[TBL] [Abstract][Full Text] [Related]
5. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
6. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
9. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
10. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
[TBL] [Abstract][Full Text] [Related]
11. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
13. Transplant in AML with measurable residual disease: proceed or defer?
Craddock C
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):528-533. PubMed ID: 36485147
[TBL] [Abstract][Full Text] [Related]
14. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia.
Blaise D; Vey N; Faucher C; Mohty M
Haematologica; 2007 Apr; 92(4):533-41. PubMed ID: 17488664
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation.
Shimoni A; Labopin M; Savani B; Volin L; Ehninger G; Kuball J; Bunjes D; Schaap N; Vigouroux S; Bacigalupo A; Veelken H; Sierra J; Eder M; Niederwieser D; Mohty M; Nagler A
J Hematol Oncol; 2016 Nov; 9(1):118. PubMed ID: 27821187
[TBL] [Abstract][Full Text] [Related]
16. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
[TBL] [Abstract][Full Text] [Related]
17. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Wang H; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):118-123. PubMed ID: 28279035
[No Abstract] [Full Text] [Related]
18. Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need.
Shimoni A; Nagler A
Best Pract Res Clin Haematol; 2011 Sep; 24(3):369-79. PubMed ID: 21925090
[TBL] [Abstract][Full Text] [Related]
19. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison.
Mohty M; de Lavallade H; Ladaique P; Faucher C; Vey N; Coso D; Stoppa AM; Gastaut JA; Blaise D
Leukemia; 2005 Jun; 19(6):916-20. PubMed ID: 15843817
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia.
Hamadani M; Mohty M; Kharfan-Dabaja MA
Cancer Control; 2011 Oct; 18(4):237-45. PubMed ID: 21976242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
